Published • loading... • Updated
Axsome: Q3 Earnings Snapshot – WTOP News
The healthcare group beat profit forecasts as higher sales and productivity gains offset recall costs, while it set aside €288 million for a DOJ settlement.
- Axsome Therapeutics reported Q3 2026 revenue of $260 million, a 52% year-over-year increase. The company also narrowed its net loss to $12.9 million, down from $47.2 million in the prior-year period.
- Advancing its 10-program neuroscience pipeline, Axsome expects top-line results for its ENGAGE Phase III trial in the first quarter of 2027. Meanwhile, the U.S. Food and Drug Administration is reviewing the AXS-12 narcolepsy NDA, with a decision expected by May 1, 2027.
- AUVELITY and Sunosi sales reached $208 million and $48.2 million, respectively. The company activated 8,200 new AUVELITY prescribers this quarter, bringing the total to 77,000 with payer coverage reaching approximately 89% of lives.
- Primary care providers now represent 40% of AUVELITY prescribers, indicating successful expansion beyond specialists. Management projects AUVELITY will generate at least $8 billion in peak annual revenue across its approved indications, reflecting the drug's substantial commercial ceiling.
- In 2027, Axsome initiates the SUMMIT Phase III trial for AXS-05 in smoking cessation. The company maintains a disciplined path toward cash-flow positivity, supported by its current cash balance and ongoing clinical development work.
Insights by Ground AI
118 Articles
118 Articles
Coverage Details
Total News Sources118
Leaning Left20Leaning Right14Center31Last UpdatedBias Distribution48% Center
Bias Distribution
- 48% of the sources are Center
48% Center
L 31%
C 48%
R 21%
Factuality
To view factuality data please Upgrade to Premium
